GTHP · XBRL financial data

Guided Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GTHP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	102	81	13	98	7	767
Cost of revenue	(41)	—	—	—	—	—
Cost of goods and services sold	—	61	81	62	5	196
Gross profit	143	20	(68)	36	2	571
Research and development	143	69	77	228	526	469
General and administrative	913	2,172	3,007	2,997	1,297	2,305
Total operating expenses	1,195	2,382	3,265	3,493	2,110	2,943
Operating income (loss)	(1,052)	(2,362)	(3,333)	(3,457)	(2,108)	(2,372)
Interest expense	1,056	1,150	582	278	381	617
Other income (expense)	773	292	(1,008)	39	18	(824)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(279)	(2,070)	(4,341)	(3,489)	(2,417)	(3,196)
Earnings per share, basic USD per share	(0.04)	(0.18)	(0.15)	(0.07)	(0.05)	(0.04)
Earnings per share, diluted USD per share	(0.04)	(0.18)	(0.15)	(0.07)	(0.05)	(0.04)
Weighted average shares, basic thousands of shares	11	13,377	32,505	—	57,339	78,414
Weighted average shares, diluted thousands of shares	11	13,377	32,505	51,131	57,339	78,414

Fiscal years (GTHP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	182	643	2,313	591	388	63
Accounts receivable	—	46	6	7	3	4
Inventory	605	571	548	632	633	448
Total current assets	896	1,637	3,004	1,393	1,197	605
Property and equipment, net	1	14	42	32	23	16
Right-of-use asset	453	372	303	227	141	686
Total assets	1,350	2,040	3,366	1,669	1,378	1,324
Accounts payable	2,419	2,362	2,186	1,991	2,094	2,416
Accrued liabilities	2,995	1,768	1,247	970	1,011	1,718
Current portion of long-term debt	28	88	17	0	—	—
Total current liabilities	8,962	5,694	4,869	4,809	6,155	6,636
Long-term debt	23	22	0	—	—	—
Lease liability, non-current	392	325	246	155	49	651
Total liabilities	12,205	7,485	6,249	5,475	6,267	7,330
Accumulated deficit	(139,956)	(142,387)	(147,359)	(151,118)	(153,709)	(157,055)
Total stockholders' equity	(10,855)	(5,445)	(2,883)	(3,806)	(4,889)	(6,006)
Total liabilities and equity	1,350	2,040	3,366	1,669	1,378	1,324
Common shares outstanding (cover page) thousands of shares	13,180	22,064	50,505	55,613	77,968	96,351

Fiscal years (GTHP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(279)	(2,070)	(4,341)	(3,489)	(2,417)	(3,196)
Stock-based compensation	310	227	176	1,806	120	377
Depreciation and amortization	0	—	—	—	—	—
Net cash from operating activities	(1,875)	(1,592)	(1,478)	(1,746)	(1,119)	(1,068)
Purchases of property and equipment	1	14	31	0	0	2
Net cash from investing activities	(1)	(14)	(31)	—	0	(2)
Proceeds from issuing common stock	0	0	1,392	0	835	567
Proceeds from long-term debt	519	—	—	—	—	—
Net cash from financing activities	1,159	2,067	3,180	24	916	745
Net change in cash	(717)	461	—	(1,722)	(203)	—

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V	18	not reported	(79)*	2.9M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Co-Diagnostics	3,650	166	(7,153)*	6.3M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Lifeward	9,448	6,623	(6,005)*	2.8M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.